Cabaletta Bio Q3 2023 cash $164.4M; CABA-201 data expected H1 2024; IND clearances for SSc and gMG

Cabaletta Bio, Inc.

2023-Q3 EPS reported -$1.18

Cash, cash equivalents and short-term investments of $164.4M as of Sept 30, 2023, up from $106.5M at Dec 31, 2022.
R&D expenses $13.8M (vs $8.2M in Q3 2022); G&A expenses $4.9M (vs $3.6M).
Initial clinical data from CABA-201 Phase 1/2 trials in lupus and/or myositis expected in first half of 2024.
IND clearances received for CABA-201 in systemic sclerosis (SSc) and generalized myasthenia gravis (gMG).
WuXi ATU selected as GMP manufacturing partner; Oxford Biomedica as lentiviral vector supplier for CABA-201.

item 2.02 item 2.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cabaletta Bio, Inc. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

Cabaletta Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-274053

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.